Anagrelide Hydrochloride
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Anagrelide Hydrochloride
- Anagrelide Hydrochloride: Drug Repurposing Evaluation — Insufficient Evidence Pack
Anagrelide Hydrochloride: Drug Repurposing Evaluation — Insufficient Evidence Pack
One-Sentence Summary
Anagrelide hydrochloride is a platelet-reducing agent used for myeloproliferative disorders such as essential thrombocythemia. The current Evidence Pack contains no TxGNN-predicted indications, no original indication records, and no safety data, making a standard drug repurposing evaluation impossible at this time. All critical data gaps must be resolved before an assessment can proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this Evidence Pack |
| Predicted New Indication | None available |
| TxGNN Prediction Score | — |
| Evidence Level | — |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack for anagrelide hydrochloride is critically incomplete across all evaluation dimensions — there are no TxGNN repurposing predictions, no original indication data, and no safety profile available. Without these foundational inputs, no repurposing candidate evaluation can be conducted.
To proceed, the following is needed:
- [DG001 — Blocking] Obtain TFDA package insert warnings and contraindications (download and parse the SmPC PDF from the TFDA website) to enable safety pre-screening
- [DG002 — High] Retrieve mechanism of action (MOA) from DrugBank API to support mechanistic relevance analysis
- Run TxGNN prediction pipeline for anagrelide hydrochloride to generate candidate indications
- Confirm active ingredient name normalization — verify whether “anagrelide hydrochloride” maps correctly to a DrugBank node (query log shows 1 result returned, but no DrugBank ID was captured)
- Investigate Taiwan regulatory status through TFDA to confirm whether the drug is actively under review or has never been submitted
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.